First, the 1975 Noble laureate in Physiology/Medicine, Prof. David Baltimore, California Institute of Technology (Caltec), California, USA, had reported the role of NFKB in the regulation of miRNA-146a in a number of prestigious journals.
Second, the 1998 Noble laureates in Physiology/Medicine, Profs. Drs Ferid M (The University of Texas, Houston, Texas, USA) and Ignarro LJ had highlighted the role of a gaseous signalling molecule Nitric oxide (NO) in a number of research papers. Subsequently, Prof. Dr Ferid M has suggested that inhibition of NOS2 (Nitric oxide synthase-2) may inhibit cancer progression.
Third, Prof. Nielsen PJ, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany, has reported in a high profile scientific journal “Journal of Immunology” on April 9, 2014 that “The Transcription Factor Bob1 Counteracts B Cell Activation and Regulates miR-146a in B Cells”
On the foundation of these interesting findings, Dr L Boominathan, Director-cum-chief scientist of GBMD, reports that: Connecting two Nobels Laureates with one idea: Bob1 suppresses cancer progression via inhibition of Nitric oxide synthase-2 (NOS-2) expression. This study provides mechanistic insights into how Bob-1-mediated NOS-2 inhibition aids cancer therapy.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Connecting two nobels with one idea: Bob1 inhibits cancer progression via inhibition of Nitric oxide synthase-2 (NOS-2) expression, 12/April/2014, 7.43 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation